Buckingham Capital Management (New York)’s Myriad Genetics MYGN Stock Holding History

Buckingham Capital Management (New York)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-223,796	Closed	-$8.38M	–	90
2016 Q1	$8.38M	Buy	223,796 +41,487	+23%	+$1.56M	0.95%	41
2015 Q4	$7.87M	Sell	182,309 -7,703	-4%	-$325K	0.97%	45
2015 Q3	$7.12M	Buy	190,012 +15,636	+9%	+$555K	0.64%	65
2015 Q2	$5.93M	Sell	174,376 -594	-0.3%	-$20.2K	0.49%	72
2015 Q1	$6.19M	Buy	+174,970	New	+$6.26M	0.54%	69

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Buckingham Capital Management (New York)'s MYGN Position: Q2 2016 in Review

Buckingham Capital Management (New York) sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 223,796 shares — an estimated $8.38M sold.

Buckingham Capital Management (New York) first reported a position in MYGN in Q1 2015 and held it in 5 quarters. The position peaked at $8.38M in Q1 2016. 253 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

Buckingham Capital Management (New York) reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
Buckingham Capital Management (New York) sold 223,796 Myriad Genetics shares in Q2 2016, an estimated $8.38M.
Buckingham Capital Management (New York) first reported a position in Myriad Genetics in Q1 2015 and held it in 5 quarters.
Buckingham Capital Management (New York)'s Myriad Genetics position peaked at $8.38M in Q1 2016.
253 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on Buckingham Capital Management (New York)'s 13F filing for Q2 2016, filed 10 Aug 2016.